= Emerging. More than 5 years before clinical availability. (24.37%, 2023)
= Expected to be clinically available in 1 to 4 years. (39.50%, 2023)
= Clinically available now. (36.13%, 2023)
MSACL 2023 : Budelier

MSACL 2023 Abstract

Self-Classified Topic Area(s): Practical Training

Podium Presentation in Colton on Thursday at 14:00 (Chair: TBA)

Interpreting Urine Drug Testing Results

Melissa Budelier
TriCore Reference Laboratories

Melissa Budelier, PhD (Presenter)
TriCore Reference Laboratories

Presenter Bio: Dr. Budelier the Medical Director of Clinical Chemistry and Toxicology at TriCore Reference Laboratories and Clinical Assistant Professor of Pathology at the University of New Mexico. Her research interests are broadly focused on developing clinically useful, mass spectrometry-based assays to improve diagnosis and treatment of human disease. Her expertise are in Toxicology/TDM, assay development and validation, and protein quantification.



This session will provide an overview of urine drug testing and will cover immunoassay and mass spectrometry methodologies, limitations and advantages of testing methods, and clinical interpretation of test results. Clinical laboratories use a variety of urine drug testing algorithms, such as screening only, screening with reflex to confirmation and direct to definitive testing. While mass spectrometry-based drug testing methods reduce the number of false positive and false negative results, no test is perfect. Using a case-based approach, we’ll review the advantages and limitations of mass spectrometry in urine drug testing and will troubleshoot unexpected results together.

Take Home Pearls:
1. Describe the advantages and limitations of various urine drug testing algorithms
2. Identify sources of false positive and false negative results in urine drug testing.
3. Interpret mass spectrometry data and troubleshoot unexpected urine drug test results.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: